Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

NCT ID: NCT01619085

Last Updated: 2022-03-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

752 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-06

Study Completion Date

2021-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All subjects

patient to receive a capsule containing Nintedanib twice a day

Group Type EXPERIMENTAL

Nintedanib

Intervention Type DRUG

Nintedanib twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nintedanib

Nintedanib twice a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BIBF 1120

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed Informed Consent consistent with International Conference on Harmonisation-Good Clinical Practices (ICH-GCP) and local laws prior to trial participation.
2. Patients from trials 1199.32 or 1199.34 who completed the 52 weeks treatment period and performed the follow-up visit.

Exclusion Criteria

1. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) \> 1.5 fold Upper Limit of Normal (ULN) (Patients who completed the parent trial with transaminase values \> 1.5 fold ULN but \< 3 fold ULN are considered eligible)
2. Bilirubin \> 1.5 fold ULN
3. Bleeding risk
4. Planned major surgery within the next 3 months, including lung transplantation, major abdominal or major intestinal surgery.
5. New major thrombo-embolic events developed after completion of the parent trial.
6. Time period \> 12 weeks between Visit 9 of the parent trial and Visit 2 of this study.
7. Usage of any investigational drug after completion of the parent trial or planned usage of a specific investigational drug during the course of this trial.
8. A disease or condition which in the opinion of investigator may put the patient at risk because of participation in this trial or limit the patients' ability to participate in this trial.
9. Alcohol or drug abuse which in the opinion of the investigator would interfere with trial participation.
10. Pregnant women or women who are breast feeding or of child bearing potential not using two effective methods of birth control (one barrier and one highly effective non-barrier) for at least 1 month prior to Visit 2 and/or not committing to using it until 3 months after end of treatment.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jasper Summit Research, LLC

Jasper, Alabama, United States

Site Status

Pulmonary Associates

Phoenix, Arizona, United States

Site Status

University of California

Los Angeles, California, United States

Site Status

University of California

San Francisco, California, United States

Site Status

Sansum Clinic

Santa Barbara, California, United States

Site Status

Stanford University Medical Center

Stanford, California, United States

Site Status

University of California

Torrance, California, United States

Site Status

Western Connecticut Medical Group

Danbury, Connecticut, United States

Site Status

Pulmonary Assoc of Stamford

Stamford, Connecticut, United States

Site Status

Cleveland Clinic

Weston, Florida, United States

Site Status

Georgia Clinical Research

Austell, Georgia, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Via Christi Clinic, PA

Wichita, Kansas, United States

Site Status

Baptist Health Lexington

Lexington, Kentucky, United States

Site Status

Minnesota Lung Center

Minneapolis, Minnesota, United States

Site Status

The Lung Research Center, LLC

Chesterfield, Missouri, United States

Site Status

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Pulmonary and Critical Care Associates

Albany, New York, United States

Site Status

Jamaica Hospital Medical Center

Jamaica, New York, United States

Site Status

New York Presbyterian Hospital

New York, New York, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

ID Clinical Research, LTD

Toledo, Ohio, United States

Site Status

The Oregon Clinic

Portland, Oregon, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

FDC Seifer PLC Pulmonary

Shelbyville, Tennessee, United States

Site Status

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

DCOL Center for Clinical Research

Longview, Texas, United States

Site Status

Metroplex Pul and Sleep Ctr

McKinney, Texas, United States

Site Status

Diagnostics Research Group

San Antonio, Texas, United States

Site Status

Vermont Lung Center

Colchester, Vermont, United States

Site Status

Inova Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Lynchburg Pulmonary Associates

Lynchburg, Virginia, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Repatriation General Hospital

Concord, New South Wales, Australia

Site Status

Frankston Hospital

Frankston, Victoria, Australia

Site Status

Alfred Hospital

Melbourne, Victoria, Australia

Site Status

ULB Hopital Erasme

Brussels, , Belgium

Site Status

Brussels - UNIV UZ Brussel

Brussels, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

Yvoir - UNIV UCL de Mont-Godinne

Yvoir, , Belgium

Site Status

QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

St. Joseph's Healthcare Hamilton

Hamilton, Ontario, Canada

Site Status

Instituto Nacional del Tórax

Santiago, , Chile

Site Status

Peking University People's Hospital

Beijing, , China

Site Status

Beijing Friendship Hospital

Beijing, , China

Site Status

Peking Union Medical College Hospital

Beijing, , China

Site Status

Xiangya Hospital, Central South University

Changsha, , China

Site Status

West China Hospital

Chengdu, , China

Site Status

The First Affiliated Hospital of Nanchang University

Nanchang, , China

Site Status

Zhongshan Hospital Fudan University

Shanghai, , China

Site Status

Shanghai Pulmonary Hospital

Shanghai, , China

Site Status

General Hospital of Shenyang Military Region

Shenyang, , China

Site Status

Xijing Hospital

Xi'an, , China

Site Status

General Hospital of Ningxia Medical University

Yinchuan, , China

Site Status

Thomayer Hospital

Prague, , Czechia

Site Status

University Hospital Na Bulovce, Prague

Prague, , Czechia

Site Status

Masaryk Hospital, Usti nad Labem

Ústí nad Labem, , Czechia

Site Status

HYKS Keuhkosairauksien tutkimusyksikkö

Helsinki, , Finland

Site Status

Mehiläinen Kielotie, Vantaa

Vantaa, , Finland

Site Status

HOP Avicenne

Bobigny, , France

Site Status

HOP Bocage

Dijon, , France

Site Status

HOP Calmette

Lille, , France

Site Status

HOP Louis Pradel

Lyon, , France

Site Status

HOP Nord

Marseille, , France

Site Status

HOP Arnaud de Villeneuve

Montpellier, , France

Site Status

HOP Pasteur

Nice, , France

Site Status

HOP Européen G. Pompidou

Paris, , France

Site Status

HOP Bichat

Paris, , France

Site Status

HOP Tenon

Paris, , France

Site Status

HOP Maison Blanche

Reims, , France

Site Status

HOP Pontchaillou

Rennes, , France

Site Status

HOP Larrey

Toulouse, , France

Site Status

CIMS Studienzentrum Bamberg GmbH

Bamberg, , Germany

Site Status

Helios Klinikum Emil von Behring

Berlin, , Germany

Site Status

Evangelische Lungenklinik Berlin

Buch, , Germany

Site Status

Universitätsklinikum Carl Gustav Carus Dresden

Coswig, , Germany

Site Status

Klinik Donaustauf

Donaustauf, , Germany

Site Status

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

Essen, , Germany

Site Status

Universitätsklinikum Freiburg

Freiburg/Breisgau, , Germany

Site Status

Universitätsklinikum Gießen und Marburg GmbH

Giessen, , Germany

Site Status

Universitätsmedizin Greifswald

Greifswald, , Germany

Site Status

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH

Großhansdorf, , Germany

Site Status

Universitätsklinikum Heidelberg

Heidelberg, , Germany

Site Status

Lungenfachklinik Immenhausen

Immenhausen, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, , Germany

Site Status

Klinikum der Universität München - Campus Großhadern

München, , Germany

Site Status

Universitätsklinikum Münster

Münster, , Germany

Site Status

Athens Hospital of Chest Diseases "Sotiria"

Athens, , Greece

Site Status

University Hospital of Heraklion, University Pulmonology Cl

Heraklion, , Greece

Site Status

General University Hospital of Larissa

Larissa, , Greece

Site Status

Mehta Hospital & Cardiopulmonary Care Centre

Ahmedabad, , India

Site Status

Chest & Maternity Center

Bangalore, , India

Site Status

Asthma Bhawan

Jaipur, , India

Site Status

National Allergy Asthma Bronchitis Institute, Kolkata

Kolkata, , India

Site Status

P.D. Hinduja National Hospital

Mumbai, , India

Site Status

Jahingir Clinical Development Centre

Pune, , India

Site Status

Mater Misericordiae University Hospital

Dublin, , Ireland

Site Status

Rabin Medical Center Beilinson

Petah Tikva, , Israel

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

Osp. Clin. SS. Anunziata

Chieti Scalo, , Italy

Site Status

Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli

Forlì, , Italy

Site Status

Osp. S. Giuseppe Fatebenefratelli

Milan, , Italy

Site Status

Università di Modena e Reggio Emilia

Modena, , Italy

Site Status

A.O. San Gerardo di Monza

Monza, , Italy

Site Status

Università Federico II

Napoli, , Italy

Site Status

Università degli Studi Padova

Padua, , Italy

Site Status

Ospedale di Cisanello

Pisa, , Italy

Site Status

Ospedale di Cisanello

Pisa, , Italy

Site Status

Pol. Universitario Tor Vergata

Roma, , Italy

Site Status

A.O.U. Senese Policlinico Santa Maria alle Scotte

Siena, , Italy

Site Status

Nagoya University Hospital

Aichi, Nagoya, , Japan

Site Status

Tosei General Hospital

Aichi, Seto, , Japan

Site Status

Ogaki Municipal Hospital

Gifu, Ogaki, , Japan

Site Status

National Hospital Organization Himeji Medical Center

Himeji, Hyogo, , Japan

Site Status

Kobe City Medical Center General Hospital

Hyogo, Kobe, , Japan

Site Status

Ibarakihigashi National Hospial

Ibaraki, Naka-gun, , Japan

Site Status

Toranomon Hospital Kajigaya

Kanagawa, Kawasaki, , Japan

Site Status

Kanagawa Cardiovascular and Respiratory Center

Kanagawa, Yokohama, , Japan

Site Status

Tohoku University Hospital

Miyagi, Sendai, , Japan

Site Status

Tenri Hospital

Nara, Tenri, , Japan

Site Status

Kindai University Hospital

Osaka, Osaka-sayama, , Japan

Site Status

Saitama Cardiovascular and Respiratory Center

Saitama, Kumagaya, , Japan

Site Status

National Hospital Organization Kinki-Chuo Chest Medical Center

Sakai, Osaka, , Japan

Site Status

Jichi Medical University Hospital

Tochigi, Shimotsuke, , Japan

Site Status

Tokushima University Hospital

Tokushima, Tokushima, , Japan

Site Status

Tokyo Medical and Dental University

Tokyo, Bunkyo-ku, , Japan

Site Status

Nippon Medical School Hospital

Tokyo, Bunkyo-ku, , Japan

Site Status

Fukujuji Hospital

Tokyo, Kiyose, , Japan

Site Status

Toranomon Hospital

Tokyo, Minato-ku, , Japan

Site Status

The Jikei University Hospital

Tokyo, Minato-ku, , Japan

Site Status

Toho University Omori Medical Center

Tokyo, Ota-ku, , Japan

Site Status

JR Tokyo General Hospital

Tokyo, Shibuya-ku, , Japan

Site Status

Tokyo Medical University Hospital

Tokyo, Shinjuku-ku, , Japan

Site Status

Center Hospital of the National Center for Global Health and Medicine

Tokyo, Shinjuku-ku, , Japan

Site Status

Tottori University Hospital

Tottori, Yonago, , Japan

Site Status

Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas

Mexico City, , Mexico

Site Status

OLVG, locatie Oosterpark

Amsterdam, , Netherlands

Site Status

St. Antonius ziekenhuis, locatie Nieuwegein

Nieuwegein, , Netherlands

Site Status

Erasmus Medisch Centrum

Rotterdam, , Netherlands

Site Status

CHUC - Centro Hospitalar e Universitário de Coimbra, EPE

Coimbra, , Portugal

Site Status

CHLC, EPE - Hospital de Santa Marta

Lisbon, , Portugal

Site Status

Centro Hospitalar Lisboa Norte Hospital Pulido Valente

Lisbon, , Portugal

Site Status

Centro Hospitalar Universitário São João,EPE

Porto, , Portugal

Site Status

Centro Hospitalar de Vila Nova de Gaia

Vila Nova de Gaia, , Portugal

Site Status

Scientific Research Institute of Pulmonology

Saint Petersburg, , Russia

Site Status

Soon Chun Hyang University Hospital Bucheon

Bucheon-si, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Soonchunhyang University Hospital Seoul

Seoul, , South Korea

Site Status

The Catholic University of Korea, Yeouido St.Mary's Hospital

Seoul, , South Korea

Site Status

Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Clínic de Barcelona

Barcelona, , Spain

Site Status

Hospital de Bellvitge

L'Hospitalet de Llobregat, , Spain

Site Status

Hospital Nuestra Señora de Valme

Seville, , Spain

Site Status

Ankara Universitesi Tip Fakultesi

Ankara, , Turkey (Türkiye)

Site Status

Istanbul Universitesi Cerrahpasa Tip Fakultesi

Istanbul, , Turkey (Türkiye)

Site Status

Yedikule Gog. Hst. EAH

Istanbul, , Turkey (Türkiye)

Site Status

Ege Universitesi T.F.

Izmir, , Turkey (Türkiye)

Site Status

Dr.Suat Seren EAH

Izmir, , Turkey (Türkiye)

Site Status

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status

Queen Elizabeth Hospital

Birmingham, , United Kingdom

Site Status

Birmingham Heartlands Hospital

Birmingham, , United Kingdom

Site Status

St James's University Hospital

Leeds, , United Kingdom

Site Status

Aintree University Hospital

Liverpool, , United Kingdom

Site Status

Royal Brompton Hospital

London, , United Kingdom

Site Status

Churchill Hospital

Oxford, , United Kingdom

Site Status

Southmead Hospital

Westbury on Trym, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Canada Chile China Czechia Finland France Germany Greece India Ireland Israel Italy Japan Mexico Netherlands Portugal Russia South Korea Spain Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.

Reference Type DERIVED
PMID: 30224318 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-002766-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1199.33

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.